Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease ...

Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) ('Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to ...

Calidi Biotherapeutics announced a public offering of 5 million shares at $0.85 each, aiming for $4.25 million in proceeds. Quiver AI Summary Calidi Biotherapeutics, Inc. announced the pricing of ...

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ('Calidi” or the 'Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease.